Metrics & Benchmarks

>

Latest News

© JHVEPhoto - ©  JHVEPhoto - stock.adobe.com
FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

August 27th 2025

FDA approves COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax targeting the LP.8.1 sublineage of SARS-CoV-2, with eligibility limited to adults aged 65 years and older and those with underlying medical conditions that place them with a high risk for severe disease.

Image Credit: Adobe Stock Images/Robin
Phase III NIMBLE Trial Demonstrates Cemdisiran Efficacy in Generalized Myasthenia Gravis

August 27th 2025

Credit: Dzmitry | stock.adobe.com. SMA can range from severe cases that develop during infancy to milder forms of the disease that manifest later in life.
Evrysdi Helps Presymptomatic Infants with Spinal Muscular Atrophy Sit, Stand, and Walk in Phase II Trial

August 27th 2025

Phase I/II RAINFOL-01 Trial Results Lead to FDA Breakthrough Designation for Genmab’s Rina-S for Advanced Endometrial Cancer
Phase I/II RAINFOL-01 Trial Results Lead to FDA Breakthrough Designation for Genmab’s Rina-S for Advanced Endometrial Cancer

August 26th 2025

Theravance Biopharma Completes Phase III CYPRESS Trial Enrollment for Novel Norepinephrine Reuptake Inhibitor in Multiple System Atrophy
Theravance Biopharma Completes Phase III CYPRESS Trial Enrollment for Novel Norepinephrine Reuptake Inhibitor in Multiple System Atrophy

August 25th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.